Stock MLAB MESA LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mesa Laboratories, Inc.

Equities

MLAB

US59064R1095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
103.2 USD +1.37% Intraday chart for Mesa Laboratories, Inc. +2.43% -1.51%
04-08 Mesa Laboratories, Inc. Amends and Restates Its Senior Secured Credit Agreement with Syndicate of Banks Led by JPMorgan Chase Bank, N.A CI
04-05 Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 891.7 988.1 1,250 1,337 934.1 556.6 - -
Enterprise Value (EV) 1 891.7 988.1 1,131 1,506 1,084 556.6 556.6 556.6
P/E ratio 124 x 729 x 380 x 728 x 1,028 x -1,876 x 275 x 62.9 x
Yield 0.28% - 0.26% 0.25% 0.37% 0.62% 0.62% 0.62%
Capitalization / Revenue 8.65 x 8.4 x 9.33 x 7.25 x 4.26 x 2.63 x 2.37 x 2.19 x
EV / Revenue 8.65 x 8.4 x 9.33 x 7.25 x 4.26 x 2.63 x 2.37 x 2.19 x
EV / EBITDA 37.2 x 31.7 x 31.8 x 32.5 x 18.8 x 11.3 x 9.61 x 8.42 x
EV / FCF 30.4 x 39.4 x 35.6 x 38.4 x 39.9 x 13.7 x 12.3 x 11.2 x
FCF Yield 3.29% 2.54% 2.81% 2.6% 2.51% 7.31% 8.14% 8.91%
Price to Book 8.06 x 4.49 x 3.08 x 3.41 x 2.38 x 1.39 x 1.37 x 1.34 x
Nbr of stocks (in thousands) 3,868 4,370 5,132 5,246 5,346 5,394 - -
Reference price 2 230.5 226.1 243.5 254.9 174.7 103.2 103.2 103.2
Announcement Date 03/06/19 01/06/20 01/06/21 31/05/22 25/05/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 103.1 117.7 133.9 184.3 219.1 211.7 234.9 254
EBITDA 1 23.98 31.13 39.29 41.16 49.68 49.3 57.9 66.1
EBIT 1 14.56 18.14 12.36 37.9 45.82 44.2 52.65 60.7
Operating Margin 14.11% 15.42% 9.23% 20.56% 20.92% 20.88% 22.41% 23.9%
Earnings before Tax (EBT) 1 8.623 3.433 2.303 3.574 -0.389 -1 2.7 12
Net income 1 7.484 1.349 3.274 1.871 0.93 -0.3 2.1 9.4
Net margin 7.26% 1.15% 2.44% 1.01% 0.42% -0.14% 0.89% 3.7%
EPS 2 1.860 0.3100 0.6400 0.3500 0.1700 -0.0550 0.3750 1.640
Free Cash Flow 1 29.29 25.06 35.08 34.79 23.44 40.7 45.3 49.6
FCF margin 28.4% 21.29% 26.19% 18.87% 10.7% 19.23% 19.28% 19.53%
FCF Conversion (EBITDA) 122.14% 80.5% 89.3% 84.52% 47.18% 82.56% 78.24% 75.04%
FCF Conversion (Net income) 391.39% 1,857.75% 1,071.5% 1,859.49% 2,520.32% - 2,157.14% 527.66%
Dividend per Share 2 0.6400 - 0.6400 0.6400 0.6400 0.6400 0.6400 0.6400
Announcement Date 03/06/19 01/06/20 01/06/21 31/05/22 25/05/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 35.84 54.7 58.88 50.45 58.75 54.29 55.59 50.64 53.16 53.47 55.27 57.2 61.5 59 56
EBITDA 1 10.52 8.028 12.72 6.972 16.42 14.04 12.25 10.44 11.22 11.98 13.7 - - - -
EBIT 1 10.12 13.78 11.65 6.158 15.47 12.86 10.71 9.524 10.31 10.9 12.5 13 13.1 13 13
Operating Margin 28.22% 25.19% 19.79% 12.21% 26.34% 23.68% 19.27% 18.81% 19.39% 20.39% 22.62% 22.73% 21.3% 22.03% 23.21%
Earnings before Tax (EBT) 1 4.543 -2.341 -0.046 -5.412 3.384 1.916 -0.277 -0.937 -1.325 1.946 -0.7 - 0.2 0.3 0.5
Net income 1 3.72 -2.06 -1.784 -1.438 1.306 0.451 0.611 -0.549 -1.23 2.116 -0.65 - 0.1 0.3 0.3
Net margin 10.38% -3.77% -3.03% -2.85% 2.22% 0.83% 1.1% -1.08% -2.31% 3.96% -1.18% - 0.16% 0.51% 0.54%
EPS 2 0.7000 -0.3900 -0.3400 -0.2700 0.2400 0.0800 0.1100 -0.1000 -0.2300 0.3900 -0.1150 - 0.0300 0.0500 0.0600
Dividend per Share 2 0.1600 0.1600 0.1600 0.1600 0.1600 0.1600 0.1600 0.1600 0.1600 0.1600 0.1600 - - - -
Announcement Date 04/11/21 03/02/22 31/05/22 04/08/22 03/11/22 06/02/23 25/05/23 03/08/23 06/11/23 05/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - 169 150 - - -
Net Cash position - - 118 - - - - -
Leverage (Debt/EBITDA) - - - 4.106 x 3.026 x - - -
Free Cash Flow 1 29.3 25.1 35.1 34.8 23.4 40.7 45.3 49.6
ROE (net income / shareholders' equity) 16.9% 17% 12.9% 10.9% 11% - 13.1% 14.1%
ROA (Net income/ Total Assets) 11.1% 9.76% 8% 6.69% 6.34% - 7.5% 8.6%
Assets 1 67.53 13.82 40.94 27.97 14.66 - 28 109.3
Book Value Per Share 2 28.60 50.30 79.00 74.80 73.30 74.40 75.20 77.10
Cash Flow per Share 2 7.580 - 4.090 7.350 5.220 6.370 7.350 8.730
Capex 1 1.26 1.5 1.99 4.43 4.54 3.5 6 9
Capex / Sales 1.22% 1.27% 1.49% 2.4% 2.07% 1.65% 2.55% 3.54%
Announcement Date 03/06/19 01/06/20 01/06/21 31/05/22 25/05/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Mesa Laboratories, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
103.2 USD
Average target price
130 USD
Spread / Average Target
+25.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
MESA LABORATORIES, INC. Stock Mesa Laboratories, Inc.
-1.51% 557M
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. MLAB Stock
  4. Financials Mesa Laboratories, Inc.